Evidence map›Paper›PMID 35227054›Full record

ArticleTurkish journal of pharmaceutical sciences2022

The Nanosuspension Formulations of Daidzein: Preparation and

Afife Büşra Uğur Kaplan, Naile Öztürk, Meltem Çetin, İmran Vural, Tuba Öznülüer Özer

Open access · diamondAbstract read
In one paragraph

Article in Turkish journal of pharmaceutical sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Research progress on the preparation and application of flavonoid nanocrystals.Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2023
    Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Afife Büşra Uğur KaplanAtatürk University Faculty of Pharmacy, Department of Pharmaceutical Technology, Erzurum, TurkeyORCID 0000-0003-2222-8789
Naile Öztürkİnönü University Faculty of Pharmacy, Department of Pharmaceutical Technology, Malatya, TurkeyORCID 0000-0002-7617-8433
Meltem ÇetinAtatürk University Faculty of Pharmacy, Department of Pharmaceutical Technology, Erzurum, TurkeyORCID 0000-0003-4009-2432
İmran VuralHacettepe University Faculty of Pharmacy, Department of Pharmaceutical Technology, Ankara, TurkeyORCID 0000-0002-1627-3834
Tuba Öznülüer ÖzerAtatürk University Faculty of Science, Department of Chemistry, Erzurum, TurkeyORCID 0000-0001-5148-2984
Atatürk University · TRInonu University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Daidzein (DZ), a water-insoluble isoflavone, has many beneficial effects (anti-inflammatory, antioxidant, and anticancer effects, etc.) on human health. DZ has a very low oral bioavailability related to its physicochemical properties (low solubility, intense metabolism of DZ in the intestine and liver). This study aimed to prepare and Materials and Methods: DZ nanosuspension formulations were prepared with media milling technique using zirconium oxide beads as milling media. Pluronic F127 and polyvinylpyrrolidone (PVP) K30 (formulation A; F-A) and sodium dodecyl sulfate (SDS) (SDS + pluronic F127 + PVP K30; formulation B; F-B) were used as stabilizers. The nanosuspension formulations were evaluated for morphological properties, particle sizes, zeta potential, DZ content, saturation solubility, dissolution, and their cytotoxic effects on RG2 glioblastoma tumor cells. Results: F-A and F-B formulations were nanosized (in the range of about 181-235 nm) and had negative zeta potential values before and after lyophilization. The DZ content of F-A and F-B formulations were found to be 93.68±0.78% and 89.75±0.49%, respectively. Fourier transform infrared spectroscopy analysis showed that there was no significant interaction between DZ and the excipients. Differential scanning calorimetry and X-ray diffraction analyses confirmed no change in the crystal structure of DZ in F-A and F-B formulations. Conclusion: In this study, the nanosuspension formulations were successfully prepared and characterized

Indexed as

CytotoxicitydaidzeinFTIR analysismedia millingnanosuspension

Identifiers

PMID35227054
PMCPMC8892555
OpenAlexW3179636298

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.